Anzeige
Meldung des Tages: Unter dem Radar, voll finanziert: Beginnt jetzt der nächste Gold-Run?

Immunic News

Aktie
WKN:  A2PHD4 ISIN:  US4525EP1011 US-Symbol:  IMUX Branche:  Biotechnologie Land:  USA
1,04 €
+0,048 €
+4,84%
07:27:06 Uhr
Depot/Watchlist
Marktkapitalisierung *
47,04 Mio. €
Streubesitz
61,15%
KGV
-0,79
Index-Zuordnung
-

Immunic News

03.06.25 - PR Newswire
Immunic, Inc. Announces Closing of Oversubscribed $65 Million Underwritten Public Offering
Immunic, Inc. Announces Closing of Oversubscribed $65 Million Underwritten Public Offering PR Newswire
02.06.25 - EQS
EQS-News: Immunic to Participate in Investor, Scientific and Industry Conferences in June
Issuer: Immunic AG / Key word(s): Conference Immunic to Participate in Investor, Scientific and Industry Conferences in June 02.06.2025 / 12:30 CET/CEST The issuer is solely ...
02.06.25 - PR Newswire
Immunic to Participate in Investor, Scientific and Industry Conferences in June
Immunic to Participate in Investor, Scientific and Industry Conferences in June PR Newswire
29.05.25 - PR Newswire
Immunic, Inc. Announces Pricing of Oversubscribed $65 Million Underwritten Public Offering
Immunic, Inc. Announces Pricing of Oversubscribed $65 Million Underwritten Public Offering PR Newswire
28.05.25 - PR Newswire
Immunic, Inc. Announces Proposed Public Offering
Immunic, Inc. Announces Proposed Public Offering PR Newswire
02.05.25 - EQS
EQS-News: Immunic to Participate in Scientific and Industry Conferences in May
Issuer: Immunic AG / Key word(s): Conference Immunic to Participate in Scientific and Industry Conferences in May 02.05.2025 / 12:30 CET/CEST The issuer is solely responsible ...
02.05.25 - PR Newswire
Immunic to Participate in Scientific and Industry Conferences in May
Immunic to Participate in Scientific and Industry Conferences in May PR Newswire
30.04.25 - EQS
EQS-News: Immunic Announces Vidofludimus Calcium Reduced Risk of Disability Worsening by 30% in Primary Progressive Multiple Sclerosis Patients from Phase 2 CALLIPER Trial
Issuer: Immunic AG / Key word(s): Study results Immunic Announces Vidofludimus Calcium Reduced Risk of Disability Worsening by 30% in Primary Progressive Multiple Sclerosis ...
30.04.25 - PR Newswire
Immunic Announces Vidofludimus Calcium Reduced Risk of Disability Worsening by 30% in Primary Progressive Multiple Sclerosis Patients from Phase 2 CALLIPER Trial
Immunic Announces Vidofludimus Calcium Reduced Risk of Disability Worsening by 30% in Primary Progressive Multiple Sclerosis Patients from Phase 2 CALLIPER Trial PR ...

Newssuche

Videos

newspaper
07.04.26 +3,85%
Technical Trading: DAX Long kurzfristig
DAX Long Typ: Turbo Open End WKN: VJ9H40 Hebel:11,30 Laufzeit: OpenEnd Einstieg: Market ... Mehr »